Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
American Journal of Perinatology · 01.04.2026 · 43 (05) · 648-656
DOI: 10.1055/a-2666-5642 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.04.2026. Verfasst von Heidi Tiller und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Hauptthemen laut MEDLINE: Thrombocytopenia, Neonatal Alloimmune, Antibodies, Monoclonal, Humanized, Fetal Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.
Abstract (Originalsprache)
Nipocalimab, a neonatal Fc receptor blocker, inhibits transplacental transfer of maternal immunoglobulin G (IgG) and lowers circulating maternal IgG levels. In a phase 2 study, nipocalimab demonstrated evidence of safety and efficacy in delaying or preventing fetal anemia in early-onset severe hemolytic disease of the fetus and newborn, suggesting a potential benefit in other IgG alloantibody-mediated perinatal diseases, including fetal and neonatal alloimmune thrombocytopenia (FNAIT). The phase 3 FREESIA-1 study aims to evaluate the safety and efficacy of nipocalimab in at-risk FNAIT pregnancies. This multicenter, placebo-controlled, double-blind, phase 3 study will enroll human platelet antigen (HPA)-1a-alloimmunized pregnant individuals with an HPA-1a-positive fetus and prior FNAIT-affected pregnancy without intracranial hemorrhage or severe bleeding in the fetus/newborn. Participants will be randomized 2:1 to weekly intravenous nipocalimab or placebo at 13 to 18 weeks of gestation until delivery. Maternal participants will receive ultrasound monitoring approximately every 2 weeks during treatment. Neonates will receive a cranial ultrasound scan, platelet count assessment, and, if needed, platelet transfusion. Maternal participants will be followed for 24 weeks and neonates/infants for 104 weeks. The primary endpoint is an adverse outcome of fetal death or adjudicated severe bleeding in utero up to 1 week postbirth, or neonatal platelet count at birth < 30 × 109/L. Key secondary endpoints include adjudicated bleeding in utero up to the first week postbirth in fetuses/neonates and platelet count at birth in neonates. Additional secondary endpoints in fetuses/neonates include death; platelet count at birth
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
- Department of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway.
- Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
- Johnson & Johnson, Spring House, Pennsylvania.
- Johnson & Johnson, Beerse, Belgium.
- Johnson & Johnson, Biologics BV, Leiden, The Netherlands.
ORCID-Profile: Heidi Tiller
Förderung
- Johnson & Johnson
Zitieren
APA
Tiller, H., Tiblad, E., Baker, P., Van Valkenburgh, H., Heerwegh, D., & Keshinro, B. (2026). Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology, 43(05), 648-656. https://doi.org/10.1055/a-2666-5642
Vancouver
Tiller H, Tiblad E, Baker P, Van Valkenburgh H, Heerwegh D, Keshinro B. Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology. 2026;43(05):648-656. doi:10.1055/a-2666-5642
BibTeX
@article{Tiller2026,
author = {Tiller, Heidi and Tiblad, Eleonor and Baker, Pamela and Van Valkenburgh, Hillary and Heerwegh, Dirk and Keshinro, Babajide},
title = {Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia},
journal = {American Journal of Perinatology},
year = {2026},
volume = {43},
number = {05},
pages = {648--656},
doi = {10.1055/a-2666-5642}
}
EUVIMED